Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP903397.RAXNglYKzCyWFw6LYfSX6FKTdVhVFR3LsmSto2LwTEDPM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP903397.RAXNglYKzCyWFw6LYfSX6FKTdVhVFR3LsmSto2LwTEDPM130_assertion type Assertion NP903397.RAXNglYKzCyWFw6LYfSX6FKTdVhVFR3LsmSto2LwTEDPM130_head.
- NP903397.RAXNglYKzCyWFw6LYfSX6FKTdVhVFR3LsmSto2LwTEDPM130_assertion description "[The present study revealed that plasma concentration of PAX, 5-HTTLPR genotype, -1019C/G 5-HT(1A) genotype, PAS score at baseline, and adverse effects may influence the therapeutic response to PAX in patients with PD.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP903397.RAXNglYKzCyWFw6LYfSX6FKTdVhVFR3LsmSto2LwTEDPM130_provenance.
- NP903397.RAXNglYKzCyWFw6LYfSX6FKTdVhVFR3LsmSto2LwTEDPM130_assertion evidence source_evidence_literature NP903397.RAXNglYKzCyWFw6LYfSX6FKTdVhVFR3LsmSto2LwTEDPM130_provenance.
- NP903397.RAXNglYKzCyWFw6LYfSX6FKTdVhVFR3LsmSto2LwTEDPM130_assertion SIO_000772 21688171 NP903397.RAXNglYKzCyWFw6LYfSX6FKTdVhVFR3LsmSto2LwTEDPM130_provenance.
- NP903397.RAXNglYKzCyWFw6LYfSX6FKTdVhVFR3LsmSto2LwTEDPM130_assertion wasDerivedFrom befree-2016 NP903397.RAXNglYKzCyWFw6LYfSX6FKTdVhVFR3LsmSto2LwTEDPM130_provenance.
- NP903397.RAXNglYKzCyWFw6LYfSX6FKTdVhVFR3LsmSto2LwTEDPM130_assertion wasGeneratedBy ECO_0000203 NP903397.RAXNglYKzCyWFw6LYfSX6FKTdVhVFR3LsmSto2LwTEDPM130_provenance.